Cheetah Medical completed its enrollment for the Fluid Responsiveness Evaluation in Sepsis-associated Hypotension (FRESH) trial following successful primary outcomes. The FRESH study was led by Ivor Douglas, MD, FRCP, Denver Health Medical Center. It has enrolled approximately 120 patients over the past two years and is the first multi-center, prospective, randomized, controlled study to evaluate using fluid responsiveness to drive fluid therapy in critically ill septic patients with refractory hypotension in an ICU setting.
FRESH is a prospective, randomized, controlled study evaluating the incidence of fluid responsiveness (FR) in critically ill patients with sepsis or septic shock. The FRESH study is evaluating and assessing the mean difference in fluid balance at intensive care unit (ICU) discharge and associated patient outcomes, based on a dynamic assessment of FR in septic patients with refractory hypotension in an ICU setting.
Ivor Douglas, MD, FRCPSource: AP News